Join the Oncology Voice Network. Join for Free
 Season 2, Episode 5: Embracing Opportunity with Tonia Nesheiwat

Season 2, Episode 5: Embracing Opportunity with Tonia Nesheiwat


Share This Article


In this episode of the Pharmaverse podcast, our host Michael Pietrack interviews Tonia Nesheiwat, VP of Medical Affairs at Caribou Biosciences. Covering everything from baseball teams, inspiring family journey to America, and of course the latest in the Pharmaverse. Together, they delve into Tonia's leadership style shaped by sports and family values. Tonia shares insights on the importance of mentorship, the challenges in medical affairs, and advice for aspiring leaders in the pharmaceutical industry. "I want to coach them through it." Tonia stresses the importance of working through issues, and keeping the eye on the ball. The conversation highlights the significance of hard work, the human element in leadership, and the need for continuous personal and professional growth. All the while, with a patients first mindset! Tune in for another great episode.

Be sure to subscribe!

Key Moments:

👨‍👩‍👦 Leadership traits are often instilled early in life.

👩‍🏭 Family sacrifices can shape one's work ethic and values. 

⚾ Sports can provide foundational leadership skills.

📈 Competition should be with oneself, not others.

🤝Mentorship is crucial for personal and professional growth.

📲 Effective communication is key in medical affairs.

💌 Embrace opportunities outside of your comfort zone.

📚 Education is a lifelong journey.

💉 The pharmaceutical industry is competitive but offers niches.

💕Leaders should focus on the human element of their teams. 

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN